Atlantic Union Bankshares Corp Boosts Stock Position in Merck & Co., Inc. (NYSE:MRK)

by · The Markets Daily

Atlantic Union Bankshares Corp boosted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 0.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 157,390 shares of the company’s stock after acquiring an additional 1,333 shares during the quarter. Merck & Co., Inc. accounts for approximately 1.0% of Atlantic Union Bankshares Corp’s investment portfolio, making the stock its 19th biggest position. Atlantic Union Bankshares Corp’s holdings in Merck & Co., Inc. were worth $17,873,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MRK. Darwin Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the third quarter worth $32,000. AM Squared Ltd acquired a new position in Merck & Co., Inc. during the 3rd quarter worth $34,000. Peterson Financial Group Inc. acquired a new position in Merck & Co., Inc. during the 3rd quarter worth $36,000. Itau Unibanco Holding S.A. acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at about $39,000. Finally, Abich Financial Wealth Management LLC boosted its stake in shares of Merck & Co., Inc. by 121.8% in the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MRK. BMO Capital Markets reduced their target price on shares of Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, October 3rd. Wells Fargo & Company cut their price target on Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating on the stock in a research note on Friday, November 1st. UBS Group lowered their price objective on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Finally, Guggenheim cut their target price on Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $130.86.

Read Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Up 1.5 %

Shares of NYSE:MRK opened at $103.12 on Friday. Merck & Co., Inc. has a 1-year low of $94.48 and a 1-year high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The stock has a market cap of $260.86 billion, a P/E ratio of 21.62, a P/E/G ratio of 1.48 and a beta of 0.40. The firm has a fifty day moving average price of $105.85 and a 200 day moving average price of $117.15.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. The business had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 36.42%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.13 earnings per share. Sell-side analysts predict that Merck & Co., Inc. will post 7.73 EPS for the current year.

Merck & Co., Inc. Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th will be paid a $0.81 dividend. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.77. This represents a $3.24 annualized dividend and a yield of 3.14%. The ex-dividend date is Monday, December 16th. Merck & Co., Inc.’s payout ratio is currently 64.57%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).